Patents by Inventor Benjamin F. Cravatt

Benjamin F. Cravatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carbamate compounds and methods of making and using same
    Patent number: 12018004
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: June 25, 2024
    Assignees: H. LUNDBECK A/S, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • ABHD12 inhibitors and methods of making and using same
    Patent number: 11897865
    Abstract: Provided herein are compounds and compositions useful as modulators of ABHD12. Furthermore, the subject compounds and compositions are useful as immunotherapies in treating, for instance, cancer or infectious diseases.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: February 13, 2024
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Daisuke Ogasawara, Taka-Aki Ichu, Jonathan Hulce, Benjamin F. Cravatt
  • CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME
    Publication number: 20230312499
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Application
    Filed: November 8, 2022
    Publication date: October 5, 2023
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • Cereblon modulators and uses thereof
    Patent number: 11771689
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: October 3, 2023
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
  • Photoreactive ligands and uses thereof
    Patent number: 11535597
    Abstract: Disclosed herein are methods for identifying proteins as targets for interaction with a small molecule ligand. Also disclosed herein are small molecule ligands and compositions for use in profiling druggable proteins.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: December 27, 2022
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Christopher G. Parker, Bruno Correia
  • Carbamate compounds and methods of making and using same
    Patent number: 11530189
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: December 20, 2022
    Assignees: H. LUNDBECKA/S, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20220298213
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO: 1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 22, 2022
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • CEREBLON MODULATORS AND USES THEREOF
    Publication number: 20220062248
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 3, 2022
    Inventors: Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, David WEINSTEIN, Ekaterina VINOGRADOVA
  • LYSINE REACTIVE PROBES AND USES THEREOF
    Publication number: 20210255193
    Abstract: Disclosed herein are methods and compounds for profiling a lysine reactive protein. Also described herein are methods, compounds, and compositions for identifying a small molecule fragment ligand that interacts with a reactive lysine residue.
    Type: Application
    Filed: December 31, 2020
    Publication date: August 19, 2021
    Inventors: Benjamin F. CRAVATT, Stephan M. HACKER, Keriann M. BACKUS
  • ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME
    Publication number: 20210221790
    Abstract: Provided herein are compounds and compositions useful as modulators of ABHD12. Furthermore, the subject compounds and compositions are useful as immunotherapies in treating, for instance, cancer or infectious diseases.
    Type: Application
    Filed: May 14, 2019
    Publication date: July 22, 2021
    Inventors: Daisuke OGASAWARA, Taka-Aki ICHU, Jonathan HULCE, Benjamin F. CRAVATT
  • CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME
    Publication number: 20210188793
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Application
    Filed: March 8, 2021
    Publication date: June 24, 2021
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • Carbamate compounds and methods of making and using same
    Patent number: 11021453
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for a method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: June 1, 2021
    Assignees: LUNDBECK LA JOLLA RESEARCH CENTER, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Justin S. Cisar, Cheryl A. Grice, Todd K. Jones, Micah J. Niphakis, Jae Won Chang, Kenneth M. Lum, Benjamin F. Cravatt
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20210002337
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING, Ekaterina VINOGRADOVA, Brian NORDIN, Kristen BALTGALVIS, Todd KINSELLA
  • Cereblon modulators and uses thereof
    Patent number: 10869860
    Abstract: Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: December 22, 2020
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, David Weinstein, Ekaterina Vinogradova
  • Lipid probes and uses thereof
    Patent number: 10859585
    Abstract: Disclosed herein are methods, compositions, probes, assays and kits for identifying a lipid binding protein as a drug binding target. Also disclosed herein are methods, compositions, and probes for mapping a ligand binding site on a lipid binding protein, identification of lipid binding proteins, generating drug-lipid binding protein profiles, high throughput drug screening, and identification of drugs as potential lipid binding protein ligands.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 8, 2020
    Assignee: The Scripps Research Institute
    Inventors: Benjamin F. Cravatt, Micah J. Niphakis, Kenneth Lum, Bruno Correia, Armand Cognetta, Jonathan Hulce
  • In vivo engineered cereblon protein
    Patent number: 10781239
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 22, 2020
    Assignees: VIVIDION THERAPEUTICS, INC., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: David Weinstein, Benjamin F. Cravatt, Matthew Patricelli, Dean Stamos, Gabe Simon, Benjamin Horning, Ekaterina Vinogradova, Brian Nordin, Kristen Baltgalvis, Todd Kinsella
  • CYSTEINE REACTIVE PROBES AND USES THEREOF
    Publication number: 20200292555
    Abstract: Disclosed herein are methods, compositions, probes, polypeptides, assays, and kits for identifying a cysteine containing protein as a binding target for a small molecule fragment. Also disclosed herein are methods, compositions, and probes for mapping a biologically active cysteine site on a protein and screening a small molecule fragment for interaction with a cysteine containing protein.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Inventors: Benjamin F. CRAVATT, Keriann M. BACKUS, Bruno E. CORREIA, Megan M. BLEWETT, John R. TEIJARO
  • CONJUGATED PROTEINS AND USES THEREOF
    Publication number: 20200278355
    Abstract: Disclosed herein, in certain embodiments, are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the proteins are regulated by NRF2. In some instances, also described herein are protein-binding domains that interact with a probe and/or a ligand described herein, in which the proteins are regulated by NRF2.
    Type: Application
    Filed: September 27, 2018
    Publication date: September 3, 2020
    Inventors: Benjamin F. CRAVATT, Liron BAR-PELED, Esther KEMPER
  • CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME
    Publication number: 20200270223
    Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.
    Type: Application
    Filed: December 17, 2019
    Publication date: August 27, 2020
    Inventors: Justin S. CISAR, Cheryl A. GRICE, Todd K. JONES, Micah J. NIPHAKIS, Jae Won CHANG, Kenneth M. LUM, Benjamin F. CRAVATT
  • IN VIVO ENGINEERED CEREBLON PROTEIN
    Publication number: 20200216507
    Abstract: Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.
    Type: Application
    Filed: August 8, 2019
    Publication date: July 9, 2020
    Inventors: David WEINSTEIN, Benjamin F. CRAVATT, Matthew PATRICELLI, Dean STAMOS, Gabe SIMON, Benjamin HORNING